RFP
BMRN icon

Root Financial Partners’s BioMarin Pharmaceuticals BMRN Stock Holding History

Root Financial Partners’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$120K Buy
2,116
+1,726
+443% +$101K 0.01% 500
2025
Q4 		$23.2K Buy
390
+59
+18% +$3.21K ﹤0.01% 1103
2025
Q3 		$17.9K Buy
+331
New +$18.9K ﹤0.01% 1169

Other funds holding BMRN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Root Financial Partners's BMRN Position: Q1 2026 in Review

Root Financial Partners increased its BioMarin Pharmaceuticals (BMRN) stake by 443% in Q1 2026, buying an estimated $101K and bringing the position to 2,116 shares worth $120K. The position accounts for 0.01% of the portfolio, ranked #500.

Root Financial Partners first reported a position in BMRN in Q3 2025 and has held it in 3 quarters since. 555 funds tracked by Wall St. Rank hold BMRN as of Q1 2026.

  • Root Financial Partners held 2,116 shares of BioMarin Pharmaceuticals worth $120K as of Q1 2026.
  • Root Financial Partners bought 1,726 BioMarin Pharmaceuticals shares in Q1 2026, an estimated $101K.
  • BioMarin Pharmaceuticals made up 0.01% of Root Financial Partners's portfolio in Q1 2026, its #500 holding.
  • Root Financial Partners first reported a position in BioMarin Pharmaceuticals in Q3 2025 and has held it in 3 quarters since.
  • 555 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2026.

Based on Root Financial Partners's 13F filing for Q1 2026, filed 24 Apr 2026.